menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Are You Seeing the Whole Picture? Case Reviews of Therapy Intensification for Patients with Type 2 Diabetes

3 chapters
Play All
1.00 credits
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    The management of type 2 diabetes (T2D) has evolved rapidly with new agents and changing recommendations.  Do you see the whole picture when selecting therapy for your patients? Engage in this clinical case review to see whether your treatment selection aligns with guideline recommendations and account for cardiovascular disease risks, patient-centric factors, and weight management.

  • Disclosure of Conflicts of Interest

    The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

    The following financial relationships have been provided:

    Jennifer B. Green, MD
    Sources of Funding for Research: Boehringer Ingelheim/Lilly, Merck, Roche
    Consulting Agreements: Anji, AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, Merck, NovoNordisk, Pfizer, Sanofi, Valo, Vertex 

    Tina K. Thethi, MD, MPH
    Advisor: Lilly
    Sources of Funding for Research: Bayer, Novo Nordisk
    Consulting Agreements: Novo Nordisk
    Speakers Bureau: Bayer, Lilly

    ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

  • Target Audience

    This program is intended for primary care providers in community settings who treat diverse patients with T2D.

  • Learning Objectives

    Upon completion of this activity, learners will be able to:

    • Formulate individualized management strategies to reduce long-term complications in patients with T2D
    • Describe the benefits of earlier treatment intensification and weight loss in achieving established goals for glycemic control
    • Summarize the latest research on the role of incretin-based therapies in patients with T2D, obesity, and obesity-related comorbidities
    • Optimize strategies to achieve sustained weight loss in T2D patients based on varied patient characteristics and targets
  • Accreditation and Credit Designation Statements

    The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

  • Disclaimer

    The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

    This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

    This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

  • Instructions

    This activity will take approximately 60 minutes to complete. To receive credit, learners are required to view the clinical case review and complete the posttest and evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

  • Provider(s)/Educational Partner(s)

    Provided by the Academy for Continued Healthcare Learning (ACHL).

  • Commercial Support

    This activity is supported by an educational grant from Lilly. 

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    The management of type 2 diabetes (T2D) has evolved rapidly with new agents and changing recommendations.  Do you see the whole picture when selecting therapy for your patients? Engage in this clinical case review to see whether your treatment selection aligns with guideline recommendations and account for cardiovascular disease risks, patient-centric factors, and weight management.

  • Disclosure of Conflicts of Interest

    The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

    The following financial relationships have been provided:

    Jennifer B. Green, MD
    Sources of Funding for Research: Boehringer Ingelheim/Lilly, Merck, Roche
    Consulting Agreements: Anji, AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, Merck, NovoNordisk, Pfizer, Sanofi, Valo, Vertex 

    Tina K. Thethi, MD, MPH
    Advisor: Lilly
    Sources of Funding for Research: Bayer, Novo Nordisk
    Consulting Agreements: Novo Nordisk
    Speakers Bureau: Bayer, Lilly

    ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

  • Target Audience

    This program is intended for primary care providers in community settings who treat diverse patients with T2D.

  • Learning Objectives

    Upon completion of this activity, learners will be able to:

    • Formulate individualized management strategies to reduce long-term complications in patients with T2D
    • Describe the benefits of earlier treatment intensification and weight loss in achieving established goals for glycemic control
    • Summarize the latest research on the role of incretin-based therapies in patients with T2D, obesity, and obesity-related comorbidities
    • Optimize strategies to achieve sustained weight loss in T2D patients based on varied patient characteristics and targets
  • Accreditation and Credit Designation Statements

    The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

  • Disclaimer

    The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

    This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

    This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

  • Instructions

    This activity will take approximately 60 minutes to complete. To receive credit, learners are required to view the clinical case review and complete the posttest and evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

  • Provider(s)/Educational Partner(s)

    Provided by the Academy for Continued Healthcare Learning (ACHL).

  • Commercial Support

    This activity is supported by an educational grant from Lilly. 

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule12 Apr 2024